Skip to main content
Erschienen in: Current Diabetes Reports 3/2022

17.02.2022 | Macrovascular Complications in Diabetes (R SHAH, Section Editor)

Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention

verfasst von: Eftitan Y. Akam, Akua A. Nuako, Afkera K. Daniel, Fatima Cody Stanford

Erschienen in: Current Diabetes Reports | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Cardiometabolic diseases are a leading cause of morbidity and mortality in the USA and disproportionately impact racial and ethnic minorities. Multiple factors contribute to this disparity including genetic and socioeconomic factors, the latter of which contributes to disparities both through systemic barriers such as healthcare access and by directly impacting metabolism through epigenetics and environment-related alterations in the gut microbiome. This review will discuss advances in medicine that can be used to identify, prognosticate, and treat cardiometabolic diseases, and how these may be used to address existing disparities.

Recent Findings

There is growing research aimed at identifying novel cardiometabolic disease targets and expanding the use of existing pharmacotherapies based on comorbidities. Advances in metabolomics and genomics can give insight into an individual’s unique biochemical profile, providing the means for earlier identification of disease and specific treatment targets. Moreover, developments in telehealth and related medical device technologies can expand access to underserved minority populations and improve control of chronic conditions such as diabetes and hypertension.

Summary

Precision medicine may be integral to bridging the racial gap in cardiometabolic disease outcomes. Developments in genomics, metabolomics, wearable medical devices, and telehealth can result in personalized treatments for patients that account for the socioeconomic and genetic factors that contribute to poor health outcomes in minorities. As research in this field rapidly progresses, special efforts must be made to ensure inclusion of racial and ethnic minority populations in clinical research and equal access to all treatment modalities.
Literatur
1.
Zurück zum Zitat National Center for Health, S., Health, United States, in Health, United States, 2018. 2019, National Center for Health Statistics (US): Hyattsville (MD). National Center for Health, S., Health, United States, in Health, United States, 2018. 2019, National Center for Health Statistics (US): Hyattsville (MD).
2.•
Zurück zum Zitat Virani, S.S., et al., Heart Disease and Stroke Statistics—2021 Update. Circulation, 2021. 143(8): p. e254-e743. This is a very comprehensive review of cardiovascular disease statistics, including cardiometabolic and lifestyle risk factors. Virani, S.S., et al., Heart Disease and Stroke Statistics—2021 Update. Circulation, 2021. 143(8): p. e254-e743. This is a very comprehensive review of cardiovascular disease statistics, including cardiometabolic and lifestyle risk factors.
3.•
Zurück zum Zitat Singh, G.K., et al., Widening Socioeconomic and Racial Disparities in Cardiovascular Disease Mortality in the United States, 1969-2013. Int J MCH AIDS, 2015. 3(2): p. 106-18. In this paper, researchers used population data to estimate cardiovascular disease disparities over time and found significantly increasing disparities, caused in part by improvements in mortality for high socioecnomic and majority populations. Singh, G.K., et al., Widening Socioeconomic and Racial Disparities in Cardiovascular Disease Mortality in the United States, 1969-2013. Int J MCH AIDS, 2015. 3(2): p. 106-18. In this paper, researchers used population data to estimate cardiovascular disease disparities over time and found significantly increasing disparities, caused in part by improvements in mortality for high socioecnomic and majority populations.
4.
Zurück zum Zitat Mazimba, S. and P.N. Peterson, JAHA spotlight on racial and ethnic disparities in cardiovascular disease. J Am Heart Assoc, 2021. 10(17): p. e023650. Mazimba, S. and P.N. Peterson, JAHA spotlight on racial and ethnic disparities in cardiovascular disease. J Am Heart Assoc, 2021. 10(17): p. e023650.
5.
Zurück zum Zitat Mody P, et al. Most important articles on cardiovascular disease among racial and ethnic minorities. Circ Cardiovasc Qual Outcomes. 2012;5(4):e33-41.PubMed Mody P, et al. Most important articles on cardiovascular disease among racial and ethnic minorities. Circ Cardiovasc Qual Outcomes. 2012;5(4):e33-41.PubMed
7.
Zurück zum Zitat Wang Y, Beydoun MA. The obesity epidemic in the United States–gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007;29:6–28.PubMed Wang Y, Beydoun MA. The obesity epidemic in the United States–gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev. 2007;29:6–28.PubMed
8.
Zurück zum Zitat Hales, C.M., et al., Prevalence of obesity and severe obesity among adults: United States, 2017–2018., in NCHS Data Brief. 2020, National Center for Health Statistics: Hyattsville, MD. Hales, C.M., et al., Prevalence of obesity and severe obesity among adults: United States, 2017–2018., in NCHS Data Brief. 2020, National Center for Health Statistics: Hyattsville, MD.
9.
Zurück zum Zitat Sarwar N, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.PubMed Sarwar N, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.PubMed
10.
Zurück zum Zitat Prevention, C.f.D.C.a., National Diabetes Statistics report, 2020. 2020, Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services: Atlanta, GA. Prevention, C.f.D.C.a., National Diabetes Statistics report, 2020. 2020, Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services: Atlanta, GA.
11.
12.
Zurück zum Zitat Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.PubMed Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.PubMed
13.
Zurück zum Zitat Rich NE, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(2):198-210.e2.PubMed Rich NE, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(2):198-210.e2.PubMed
15.
Zurück zum Zitat Carroll, M.D. and C.D. Fryar, Total and high-density lipoprotein cholesterol in adults: United States, 2015–2018., N.C.f.H. Statistics, Editor. 2020, NCHS Data Brief: Hyattsville, MD. Carroll, M.D. and C.D. Fryar, Total and high-density lipoprotein cholesterol in adults: United States, 2015–2018., N.C.f.H. Statistics, Editor. 2020, NCHS Data Brief: Hyattsville, MD.
16.
Zurück zum Zitat Havranek EP, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132(9):873–98.PubMed Havranek EP, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015;132(9):873–98.PubMed
17.
Zurück zum Zitat Soler-Botija C, Gálvez-Montón C, Bayés-Genís A. Epigenetic biomarkers in cardiovascular diseases. Front Genet. 2019;10:950.PubMedPubMedCentral Soler-Botija C, Gálvez-Montón C, Bayés-Genís A. Epigenetic biomarkers in cardiovascular diseases. Front Genet. 2019;10:950.PubMedPubMedCentral
18.
Zurück zum Zitat Phillips, M.L., Gut reaction: environmental effects on the human microbiota, in Environ Health Perspect. 2009. p. A198–205. Phillips, M.L., Gut reaction: environmental effects on the human microbiota, in Environ Health Perspect. 2009. p. A198–205.
19.
Zurück zum Zitat Moyer, V.A., Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2012. 157(5): p. 373–8. Moyer, V.A., Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med, 2012. 157(5): p. 373–8.
20.
Zurück zum Zitat Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143.PubMed Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143.PubMed
21.
Zurück zum Zitat Ussher JR, et al. The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease. J Am Coll Cardiol. 2016;68(25):2850–70.PubMed Ussher JR, et al. The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease. J Am Coll Cardiol. 2016;68(25):2850–70.PubMed
22.
Zurück zum Zitat Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56–64.PubMedPubMedCentral Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56–64.PubMedPubMedCentral
23.
Zurück zum Zitat Ganna, A., et al., Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease. PLoS Genet, 2014. 10(12): p. e1004801. Ganna, A., et al., Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease. PLoS Genet, 2014. 10(12): p. e1004801.
24.
Zurück zum Zitat Park, J.Y., et al., Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction. PLoS One, 2015. 10(8): p. e0135228. Park, J.Y., et al., Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction. PLoS One, 2015. 10(8): p. e0135228.
25.
Zurück zum Zitat Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124(10):4204–11.PubMedPubMedCentral Tang WH, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124(10):4204–11.PubMedPubMedCentral
26.
Zurück zum Zitat Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(3):193–205.PubMed Muoio DM, Newgard CB. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(3):193–205.PubMed
27.
Zurück zum Zitat Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–248.PubMed Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127–248.PubMed
28.
Zurück zum Zitat Cheatham SW, et al. The efficacy of wearable activity tracking technology as part of a weight loss program: a systematic review. J Sports Med Phys Fitness. 2018;58(4):534–48.PubMed Cheatham SW, et al. The efficacy of wearable activity tracking technology as part of a weight loss program: a systematic review. J Sports Med Phys Fitness. 2018;58(4):534–48.PubMed
29.
Zurück zum Zitat Lachausse RG. My student body: effects of an internet-based prevention program to decrease obesity among college students. J Am Coll Health. 2012;60(4):324–30.PubMed Lachausse RG. My student body: effects of an internet-based prevention program to decrease obesity among college students. J Am Coll Health. 2012;60(4):324–30.PubMed
30.
Zurück zum Zitat Sorgente, A., et al., Web-based interventions for weight loss or weight loss maintenance in overweight and obese people: a systematic review of systematic reviews. J Med Internet Res, 2017. 19(6): p. e229. Sorgente, A., et al., Web-based interventions for weight loss or weight loss maintenance in overweight and obese people: a systematic review of systematic reviews. J Med Internet Res, 2017. 19(6): p. e229.
31.
Zurück zum Zitat Napolitano MA, et al. Using Facebook and text messaging to deliver a weight loss program to college students. Obesity (Silver Spring). 2013;21(1):25–31. Napolitano MA, et al. Using Facebook and text messaging to deliver a weight loss program to college students. Obesity (Silver Spring). 2013;21(1):25–31.
32.
Zurück zum Zitat Strelitz J, et al. Association of weight loss and weight loss maintenance following diabetes diagnosis by screening and incidence of cardiovascular disease and all-cause mortality: an observational analysis of the ADDITION-Europe trial. Diabetes Obes Metab. 2021;23(3):730–41.PubMed Strelitz J, et al. Association of weight loss and weight loss maintenance following diabetes diagnosis by screening and incidence of cardiovascular disease and all-cause mortality: an observational analysis of the ADDITION-Europe trial. Diabetes Obes Metab. 2021;23(3):730–41.PubMed
33.
Zurück zum Zitat Sheard NF, et al. Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the american diabetes association. Diabetes Care. 2004;27(9):2266–71.PubMed Sheard NF, et al. Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the american diabetes association. Diabetes Care. 2004;27(9):2266–71.PubMed
34.
Zurück zum Zitat Vega-López S, et al. Interindividual variability and intra-individual reproducibility of glycemic index values for commercial white bread. Diabetes Care. 2007;30(6):1412–7.PubMed Vega-López S, et al. Interindividual variability and intra-individual reproducibility of glycemic index values for commercial white bread. Diabetes Care. 2007;30(6):1412–7.PubMed
35.
Zurück zum Zitat Vrolix R, Mensink RP. Variability of the glycemic response to single food products in healthy subjects. Contemp Clin Trials. 2010;31(1):5–11.PubMed Vrolix R, Mensink RP. Variability of the glycemic response to single food products in healthy subjects. Contemp Clin Trials. 2010;31(1):5–11.PubMed
36.
Zurück zum Zitat Zeevi D, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163(5):1079–94.PubMed Zeevi D, et al. Personalized nutrition by prediction of glycemic responses. Cell. 2015;163(5):1079–94.PubMed
37.
Zurück zum Zitat Qin J, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.PubMed Qin J, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60.PubMed
38.
Zurück zum Zitat Boursier J, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–75.PubMed Boursier J, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–75.PubMed
39.
Zurück zum Zitat Zhu L, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–9.PubMed Zhu L, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–9.PubMed
40.
Zurück zum Zitat Koeth RA, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85.PubMedPubMedCentral Koeth RA, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85.PubMedPubMedCentral
41.
42.
Zurück zum Zitat Gilbert JA, et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature. 2016;535(7610):94–103.PubMed Gilbert JA, et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature. 2016;535(7610):94–103.PubMed
43.
Zurück zum Zitat Zhu W, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111–24.PubMedPubMedCentral Zhu W, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111–24.PubMedPubMedCentral
44.
Zurück zum Zitat Tilg H, et al. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020;20(1):40–54.PubMed Tilg H, et al. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020;20(1):40–54.PubMed
45.
Zurück zum Zitat Rodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther. 2017;19(S3):S25-s37.PubMed Rodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. Diabetes Technol Ther. 2017;19(S3):S25-s37.PubMed
46.
Zurück zum Zitat Eiland L, Thangavelu T, Drincic A. Has technology improved diabetes management in relation to age, gender, and ethnicity? Curr Diab Rep. 2019;19(11):111.PubMed Eiland L, Thangavelu T, Drincic A. Has technology improved diabetes management in relation to age, gender, and ethnicity? Curr Diab Rep. 2019;19(11):111.PubMed
47.
Zurück zum Zitat Honigberg MC, et al. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review. JAMA Cardiology. 2020;5(10):1182–90.PubMedPubMedCentral Honigberg MC, et al. Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review. JAMA Cardiology. 2020;5(10):1182–90.PubMedPubMedCentral
48.
Zurück zum Zitat Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. J Diabetes Res. 2018;2018:4020492–4020492.PubMedPubMedCentral Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. J Diabetes Res. 2018;2018:4020492–4020492.PubMedPubMedCentral
49.
Zurück zum Zitat Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.PubMed Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.PubMed
50.
Zurück zum Zitat Mann JFE, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–48.PubMed Mann JFE, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–48.PubMed
51.
Zurück zum Zitat Wadden TA, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403–13.PubMed Wadden TA, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 Randomized Clinical Trial. JAMA. 2021;325(14):1403–13.PubMed
52.
Zurück zum Zitat Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–25.PubMed Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 Randomized Clinical Trial. JAMA. 2021;325(14):1414–25.PubMed
53.
Zurück zum Zitat McGuire DK, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiology. 2021;6(2):148–58.PubMed McGuire DK, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiology. 2021;6(2):148–58.PubMed
54.
Zurück zum Zitat Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.PubMed Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.PubMed
55.
Zurück zum Zitat Zannad F, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–29.PubMed Zannad F, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–29.PubMed
56.
Zurück zum Zitat Yancy CW, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61.PubMed Yancy CW, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136(6):e137–61.PubMed
57.
Zurück zum Zitat Cooper, L.B., et al., Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease. Journal of the American Heart Association, 2017. 6(12): p. e006540. Cooper, L.B., et al., Use of mineralocorticoid receptor antagonists in patients with heart failure and comorbid diabetes mellitus or chronic kidney disease. Journal of the American Heart Association, 2017. 6(12): p. e006540.
58.
Zurück zum Zitat Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29.PubMed Bakris GL, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219–29.PubMed
59.
Zurück zum Zitat Pitt, B., et al., Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med, 2021. Pitt, B., et al., Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med, 2021.
60.
Zurück zum Zitat Pitt B, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453–63.PubMedPubMedCentral Pitt B, et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453–63.PubMedPubMedCentral
61.
Zurück zum Zitat Libby P, Hansson GK. From focal lipid storage to systemic inflammation: JACC review topic of the week. J Am Coll Cardiol. 2019;74(12):1594–607.PubMedPubMedCentral Libby P, Hansson GK. From focal lipid storage to systemic inflammation: JACC review topic of the week. J Am Coll Cardiol. 2019;74(12):1594–607.PubMedPubMedCentral
62.
Zurück zum Zitat Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–26.PubMed Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–26.PubMed
63.
Zurück zum Zitat Cinoku, I.I., C.P. Mavragani, and H.M. Moutsopoulos, Atherosclerosis: beyond the lipid storage hypothesis. The role of autoimmunity. Eur J Clin Invest, 2020. 50(2): p. e13195. Cinoku, I.I., C.P. Mavragani, and H.M. Moutsopoulos, Atherosclerosis: beyond the lipid storage hypothesis. The role of autoimmunity. Eur J Clin Invest, 2020. 50(2): p. e13195.
64.
Zurück zum Zitat Dregan A, et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation. 2014;130(10):837–44.PubMed Dregan A, et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation. 2014;130(10):837–44.PubMed
65.
Zurück zum Zitat Murphy AJ, Febbraio MA. Immune-based therapies in cardiovascular and metabolic diseases: past, present and future. Nat Rev Immunol. 2021;21(10):669–79.PubMed Murphy AJ, Febbraio MA. Immune-based therapies in cardiovascular and metabolic diseases: past, present and future. Nat Rev Immunol. 2021;21(10):669–79.PubMed
66.
Zurück zum Zitat Shaposhnik Z, et al. The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res. 2009;50(4):623–9.PubMedPubMedCentral Shaposhnik Z, et al. The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res. 2009;50(4):623–9.PubMedPubMedCentral
67.
Zurück zum Zitat Nicholls SJ, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 Randomized Clinical Trial. JAMA. 2014;311(3):252–62.PubMed Nicholls SJ, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 Randomized Clinical Trial. JAMA. 2014;311(3):252–62.PubMed
68.
Zurück zum Zitat Wilensky RL, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14(10):1059–66.PubMedPubMedCentral Wilensky RL, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14(10):1059–66.PubMedPubMedCentral
69.
Zurück zum Zitat White HD, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702–11.PubMed White HD, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702–11.PubMed
70.
Zurück zum Zitat Ridker PM, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–62.PubMed Ridker PM, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380(8):752–62.PubMed
71.
Zurück zum Zitat Chung ES, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–40.PubMed Chung ES, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133–40.PubMed
72.
Zurück zum Zitat Esser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs. 2015;24(3):283–307.PubMed Esser N, Paquot N, Scheen AJ. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease. Expert Opin Investig Drugs. 2015;24(3):283–307.PubMed
73.
Zurück zum Zitat Bernstein LE, et al. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med. 2006;166(8):902–8.PubMedPubMedCentral Bernstein LE, et al. Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med. 2006;166(8):902–8.PubMedPubMedCentral
74.
Zurück zum Zitat Tardif JC, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9626):1761–8.PubMed Tardif JC, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9626):1761–8.PubMed
75.
Zurück zum Zitat Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.PubMed Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–31.PubMed
76.
Zurück zum Zitat Levine GN, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082–115.PubMed Levine GN, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082–115.PubMed
77.
Zurück zum Zitat Mega JL, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821–30.PubMedPubMedCentral Mega JL, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821–30.PubMedPubMedCentral
78.
Zurück zum Zitat Klein MD, et al. Clinical utility of <i>CYP2C19</i> genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention. Arterioscler Thromb Vasc Biol. 2019;39(4):647–52.PubMed Klein MD, et al. Clinical utility of <i>CYP2C19</i> genotyping to guide antiplatelet therapy in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention. Arterioscler Thromb Vasc Biol. 2019;39(4):647–52.PubMed
79.
Zurück zum Zitat Tada H, et al. Rare and deleterious mutations in ABCG5/ABCG8 genes contribute to mimicking and worsening of familial hypercholesterolemia phenotype. Circ J. 2019;83(9):1917–24.PubMed Tada H, et al. Rare and deleterious mutations in ABCG5/ABCG8 genes contribute to mimicking and worsening of familial hypercholesterolemia phenotype. Circ J. 2019;83(9):1917–24.PubMed
80.
Zurück zum Zitat Tada H, et al. Sitosterolemia, hypercholesterolemia, and coronary artery disease. J Atheroscler Thromb. 2018;25(9):783–9.PubMedPubMedCentral Tada H, et al. Sitosterolemia, hypercholesterolemia, and coronary artery disease. J Atheroscler Thromb. 2018;25(9):783–9.PubMedPubMedCentral
81.
Zurück zum Zitat Tada H, et al. Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids Health Dis. 2020;19(1):3.PubMedPubMedCentral Tada H, et al. Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene. Lipids Health Dis. 2020;19(1):3.PubMedPubMedCentral
82.
Zurück zum Zitat Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol. 2018;71(1):1–7.PubMed Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol. 2018;71(1):1–7.PubMed
83.
Zurück zum Zitat FDA approves first treatment for weight management for people with certain rare genetic conditions. 2020. FDA approves first treatment for weight management for people with certain rare genetic conditions. 2020.
84.
Zurück zum Zitat Akbari, P., et al., Sequencing of 640,000 exomes identifies <i>GPR75</i> variants associated with protection from obesity. Science, 2021. 373(6550): p. eabf8683. Akbari, P., et al., Sequencing of 640,000 exomes identifies <i>GPR75</i> variants associated with protection from obesity. Science, 2021. 373(6550): p. eabf8683.
85.
Zurück zum Zitat Hodatsu A, et al. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models. Am J Physiol Heart Circ Physiol. 2014;307(11):H1594–604.PubMed Hodatsu A, et al. Compound heterozygosity deteriorates phenotypes of hypertrophic cardiomyopathy with founder MYBPC3 mutation: evidence from patients and zebrafish models. Am J Physiol Heart Circ Physiol. 2014;307(11):H1594–604.PubMed
86.
Zurück zum Zitat Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–24.PubMedPubMedCentral Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–24.PubMedPubMedCentral
87.
Zurück zum Zitat Tada H, Kawashiri MA, Yamagishi M. Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants. J Hum Genet. 2017;62(4):453–8.PubMed Tada H, Kawashiri MA, Yamagishi M. Comprehensive genotyping in dyslipidemia: mendelian dyslipidemias caused by rare variants and Mendelian randomization studies using common variants. J Hum Genet. 2017;62(4):453–8.PubMed
88.
89.
Zurück zum Zitat Committee, P.E. Bariatric surgery procedures. 2021 [cited 2021 November 21]. Committee, P.E. Bariatric surgery procedures. 2021 [cited 2021 November 21].
90.
Zurück zum Zitat McCarty TR, Thompson CC. The current state of bariatric endoscopy. Dig Endosc. 2021;33(3):321–34.PubMed McCarty TR, Thompson CC. The current state of bariatric endoscopy. Dig Endosc. 2021;33(3):321–34.PubMed
91.
Zurück zum Zitat Coakley M, et al. Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials. J Womens Health (Larchmt). 2012;21(7):713–6. Coakley M, et al. Dialogues on diversifying clinical trials: successful strategies for engaging women and minorities in clinical trials. J Womens Health (Larchmt). 2012;21(7):713–6.
92.
93.
Zurück zum Zitat Bentley AR, Callier S, Rotimi CN. Diversity and inclusion in genomic research: why the uneven progress? J Community Genet. 2017;8(4):255–66.PubMedPubMedCentral Bentley AR, Callier S, Rotimi CN. Diversity and inclusion in genomic research: why the uneven progress? J Community Genet. 2017;8(4):255–66.PubMedPubMedCentral
94.
Zurück zum Zitat Kahn, J.M., et al., Strategies to improve diversity, equity, and inclusion in clinical trials. Cancer, 2021. Kahn, J.M., et al., Strategies to improve diversity, equity, and inclusion in clinical trials. Cancer, 2021.
95.•
Zurück zum Zitat Clark, L.T., et al., Increasing Diversity in Clinical Trials: Overcoming Critical Barriers. Current Problems in Cardiology, 2019. 44(5): p. 148-172. In this paper, the authors investigated barriers to participation in clinical trials in minority communities both through literatire review and direct interviews with stakeholers. They identified critical themes in barriers and proposed solutions for how to increase minority participation in clinical research. Clark, L.T., et al., Increasing Diversity in Clinical Trials: Overcoming Critical Barriers. Current Problems in Cardiology, 2019. 44(5): p. 148-172. In this paper, the authors investigated barriers to participation in clinical trials in minority communities both through literatire review and direct interviews with stakeholers. They identified critical themes in barriers and proposed solutions for how to increase minority participation in clinical research.
Metadaten
Titel
Racial Disparities and Cardiometabolic Risk: New Horizons of Intervention and Prevention
verfasst von
Eftitan Y. Akam
Akua A. Nuako
Afkera K. Daniel
Fatima Cody Stanford
Publikationsdatum
17.02.2022
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 3/2022
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-022-01451-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.